Medicines and Healthcare Products Regulatory Agency

CERTIFICATE NUMBER: UK GMP 17543 Insp GMP 17543/9621-0024 [H]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER

Part 1

Issued following an inspection in accordance with:

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of United Kingdom confirms the following:

The manufacturer: INTAS PHARMACEUTICALS LIMITED

Site address: PLOT NUMBERS 457,458 & 191/218P, SARKHEJ-BAVLA HIGHWAY, MATODA,

SANAND, AHMEDABAD, GUJARAT, IN-382210, India

DUNS Number: 72-592-7649

Has been inspected in connection with marketing authorisation(s) listing manufacturers located outside of the European Economic Area in accordance with Art. 19(3) of Regulation 726/2004/EC.

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2018-05-14**, it is considered that it complies with:

• The principles and guidelines of Good Manufacturing Practice laid down in Directive 2003/94/EC

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

Online EudraGMDP, Ref key: 54476 Issuance Date: 2019-05-08 Signatory: Confidential Page 1 of 3

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Medicinal Products

1 MA	NUFACTURING OPERATIONS
1.1	Sterile products
	1.1.1 Aseptically prepared (processing operations for the following dosage forms) 1.1.1.2 Lyophilisates 1.1.1.4 Small volume liquids 1.1.1.6 Other: (PFS)(en)
	1.1.2 Terminally Sterilised (processing operations for the following dosage forms)
	1.1.2.3 Small volume liquids 1.1.2.5 Other: (PFS)(en)
1.2	Non-sterile products
	1.2.1 Non-sterile products (processing operations for the following dosage forms) 1.2.1.1 Capsules, hard shell 1.2.1.11 Semi-solids Special Requirements 7 Other: for Ointments(en) 1.2.1.13 Tablets
1.4	Other products or manufacturing activity
	1.4.2 Sterilisation of active substance/ excipients/ finished product 1.4.2.1 Filtration 1.4.2.3 Moist heat
1.5	Packaging
	1.5.1 Primary Packing 1.5.1.1 Capsules, hard shell 1.5.1.13 Tablets 1.5.1.17 Other non-sterile medicinal products: Onitments(en)
	1.5.2 Secondary packing
1.6	Quality control testing
	1.6.1 Microbiological: sterility
	1.6.2 Microbiological: non-sterility
	1.6.3 Chemical/Physical

Signatory: Confidential

Clarifying remarks (for public users)

OSD I, OSD II, External Preparations, Central QC, Oncology QC, General Parenteral, Oncology Solid dose & Oncology Parenteral

2019-05-08

Name and signature of the authorised person of the Competent Authority of United Kingdom

Confidential

Medicines and Healthcare Products Regulatory Agency

Tel: Confidential
Fax: Confidential

Online EudraGMDP, Ref key: 54476

Issuance Date: 2019-05-08

Signatory: Confidential